TO THE EDITOR
I read with great attention the article by Saghaei et al. in a recent issue of your esteemed journal [1] . The article is highly interesting and thought-provoking. Of note, the past few years have seen the emergence of nimesulide as an in vitro agent with significant anti-carcinogenic properties, in addition to its primary role as an analgesic.
For example, nimesulide attenuates mammalian target of rapamycin (mTOR) signaling and thereby inhibits tissue growth in colorectal carcinomas [2] . Similarly, reduced proliferation is seen in aromatase inhibitor-insensitive breast cancer cells following administration of the nimesulide analogue JCC76 [3] . Nimesulide also enhances the effects of radiotherapy in lung carcinomas through intensification of caspase-3 and caspase-8 activation [4] . Similarly, nimesulide attenuates tumor growth in pancreatic carcinomas by inhibiting vascular endothelial growth factor (VEGF) [5] .
Similar growth inhibitory effects are seen in gastric carcinomas. These effects are mediated by increased secretion of TNF-alpha secondary to nimesulide administration [6] .
Nimesulide also downregulates the aquaporin-3 gene and attenuates the expression of the KSHV gene, resulting in apoptosis in primary effusion lymphomas [7] . In addition, nimesulide inhibits tumor growth in hepatocellular carcinomas. The apoptotic effect of nimesulide in hepatocellular carcinomas is augmented by the mDRA-6 monoclonal antibody [6] .
Nimesulide must be used with care because of the attendant risk of hepatotoxicity [8] .
Clearly, nimesulide demonstrates significant anti-neoplastic effects in vitro. Additional in vivo studies are needed to further elaborate and fully harness the anti-carcinogenic properties of nimesulide.
